Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators

US9062028B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Jeffrey A. Robl · Newtown, US
• Jun Li · Foster City, US
• Lawrence J. Kennedy · Titusville, US
• Steven J. Walker · Portage, US
• Haixia Wang · San Diego, US
• William N. Washburn · Titusville, US
• Saleem Ahmad · Wall, US
• Khehyong Ngu · Pennington, US

Key dates

• Filing date: Apr 27, 2012
• Grant date: Jun 23, 2015
• Expiry date: Apr 27, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07F9/60
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.